Use of Spectral OCT in Combination Therapy

Inclusion Criteria: * Ability to give informed consent * Patients with visual acuity of 20/40-20/320 in the study eye * Subfoveal choroidal neovascularization (CNV) must be at least 50% of the total lesion size. * Total area of lesion components other that CNV must be less than 50% of the total lesion size. * The lesion must be \< 5400microns in greatest linear dimension (GLD). * Lesion size \< 10 DA * Occult with no classic CNV lesions must have presumed recent disease progression: 1. Blood associated with the lesion at baseline 2. Loss of visual acuity in the previous 3 months: a: \> 5 letter loss (ETDRS equivalent) or b: 2 or more lines using a snellen or equivalent chart 3. \> 10% increase in GLD as assessed by fluorescein angiography in the previous 3 months Exclusion Criteria: * Presence of angioid streaks, presumed ocular histoplasmosis syndrome, pathologic myopia (-8 or more with evidence of posterior segment abnormalities consistent with pathologic myopia), or CNV secondary to causes other than AMD * Geographic atrophy in the study eye * Tear (rip) of the retinal pigment epithelium * Presence of fibrosis, hemorrhage, pigment epithelial detachments, or other hypofluorescent lesions obscuring greater than 50% of the CNV lesion * Intraocular surgery within 6 weeks of enrollment * Active or history of ocular inflammation or infection in the study eye within the last 30 days * Subretinal hemorrhage \> 50% of the total lesion * History of submacular surgery, or transpupillary thermotherapy in the study eye * Patients with intraocular pressure greater than 30 mm/Hg on 2 pressure-lowering medications * Patients with severe disciform scarring * History of intraocular surgery in the study eye including pars plana vitrectomy, except for uncomplicated cataract surgery within 60 days prior to screening * History of YAG laser posterior capsulotomy in the study eye within 30 days prior to screening * Inability to make study visits * Advanced glaucoma, uncontrolled glaucoma in the study eye (defined as intraocular pressure, IOP ≥ 25 mmHg) despite treatment with two or more topical pharmacological anti-glaucomatous medication) * Allergies to porphyrins or a known hypersensitivity to any component of Visudyne® * Patients with porphyria * Pregnancy or lactation